Iambic Therapeutics closed an oversubscribed financing of more than $100 million to accelerate development of AI‑discovered therapeutics and platform advances. The round drew strategic investors including ARK and Regeneron Ventures; company statements outlined plans to advance multiple programs and expand collaborations for AI‑designed assets. Separately, coverage notes Iambic’s AI platform has generated clinical‑stage candidates and that the firm intends to bring KIF18A and CDK programs toward the clinic. Investors signaled continued appetite for AI‑driven biotech platforms that can produce multiple programs from a single model.